Laminar Pharmaceuticals
Manufacturing · Spain · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Ctra Valldemossa Mód c-8 Km. 7,4 Parcbit...Phone Number
(978) 631-0600Website
www.laminarpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Laminar Pharmaceuticals
Laminar Pharma is a pioneering biopharmaceutical company dedicated to the discovery, design, and initial clinical development of next-generation medicines. The company specializes in a novel therapeutic approach known as melitherapy, focusing on first-in-class molecules that target membrane lipids. Laminar Pharma aims to provide reference treatments for diseases with unmet medical needs, including cancer and Alzheimer's disease. Their innovative pipeline includes products like LAM561, LAM226, and LAM204, which are currently undergoing clinical trials.Explore more
Laminar Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Laminar Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Laminar Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Laminar Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Laminar Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Laminar Pharmaceuticals has new funding data
Product Launch: Get notified when Laminar Pharmaceuticals launches new products
Earning: See what the market has to say on Laminar Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Laminar Pharmaceuticals
Click to see if Laminar Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Laminar Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to Laminar Pharmaceuticals
Compare insights from companies similar to Laminar Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Laminar Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Laminar Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Laminar Pharmaceuticals.
Laminar Pharmaceuticals Tech Stack
A closer look at the technologies used by Laminar Pharmaceuticals
See more technologies
Laminar Pharmaceuticals News & Media
Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
PALMA DE MALLORCA, Spain, July 23, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company's Phase 2b/3 clinical...Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative cancer therapy based on membrane lipid therapy, announced today optimistic results from its ongoing clinical trial evaluating LAM561 for the treatment of newly diagnosed glioblastoma (ndGBM), the most aggressive form of brain cancer, that has seen limited clinical improvement in the last 20 years. The trial, partially funded with an EU H2020 Grant (ClinGlio), has shown an improvementLaminar Pharma Raises 5.9M in a New Round of Financing - Born2Invest
Laminar Pharma raised €5.9 million, led by the Matutes family, for its growth and launch of anti-tumor drug LAM 561, aimed at glioblastoma treatment. Additional investors included the Alba Pérez Foundation and Dentol Capital. The company expects €1 billion in revenue by 2026, in collaboration with an undisclosed major pharmaceutical partner.Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for CLINGLIO, the phase 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed glioblastoma
140 patients have been recruited at sites in Spain, Italy, France and United Kingdom. The open readout of the trial is expected by late 2024. Laminar aims to submit regulatory filings or conditional marketing authorization by early 2025. PALMA DE MALLORCA, Spain, June 11, 2024...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Laminar Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Laminar Pharma is a pioneering biopharmaceutical company dedicated to the discovery, design, and initial clinical development of next-generation medicines. The company specializes in a novel therapeutic approach known as melitherapy, focusing on first-in-class molecules that target membrane lipids. Laminar Pharma aims to provide reference treatment... Read More
